NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
22/01/2025
Voltar para busca
Dado oficial do USPTO
SOCTEC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SOCTEC
ST13
US500000086364754Classe
5, 10, 42, 44
Pedido
86364754
Registro
5494819
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
63
Atualização mais recente
11/02/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 42, 44
Data de depósito
12/08/2014
Data de registro
19/06/2018
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
22/01/2025
Última transação
11/02/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
705
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
SAINT-QUENTIN-FALLAVIER, FR
Examinador
HENRY,NAKIA D
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
SKYEPHARMA PRODUCTION S.A.S.
Jagotec AG
Representantes
Molly Buck Richard RICHARD LAW GROUP
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticals having a self-orienting effectorally delivered pharmaceuticals with modified time release into the gastrointestinal system; gastro retentive pharmaceuticals; self orienting pharmaceuticals in the form of capsulescapsules consisting of segments of varied functions and absorption ratesresulting in controlled release into the gastrointestinal tract; Gastrointestinal drug delivery preparations for medicalsurgical and biological purposes; chronotherapy-focused tabletsanalgesics; Medicines for treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders; medicinal preparations for treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders; capsules for the release of colonic drug delivery; pharmaceuticals for the treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disordersmedical and veterinary preparations for body slimming purposes; capsulessuppositoriestablets and pills for pharmaceuticalmedical and veterinary purposes for the treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders; pre-filled vials containing medical diagnostic reagents; exclude goods being related to the treatment of respiratory diseases
Classe 10
inhalers for medical purposes; injection apparatusinstruments and devicesmedical apparatus in the nature of an infusion injection device for administering drugs; apparatusinstruments and devicesautomated drug delivery systems for storing and dispensing medicalsurgical and veterinary preparationscapsulespowderstablets and pills; instruments and apparatus for the administration of self-orientation therapy and prophylaxis preparations and substancesgastrointestinal drug delivery systemssyringes and fluid injectors for medical purposes; exclude goods being related to the treatment of respiratory diseases
Classe 42
Scientific and technological servicescustom design exclusively in the pharmaceuticals and medical fields; design services exclusively in the pharmaceuticals and medical fields; drug development and custom design of pharmaceuticals and medical goods; exclude services in the field of inhalation technology
Classe 44
Medical services; veterinary services; hygienic care for human beings or animals; medical analysis for the diagnosis and treatment of persons treatment or prevention of cancerinfectious diseasefungal diseasesdiseases caused by parasiteshookwormspinwormsroundwormstapewormsflukesgiardiaentameobacryptosporidiumtoxoplasmosissleeping sicknesstrichuriasisisosporiasismalariaparasitic skin disease and leishmaniasiseye diseasesdiseases of the central and peripheral nervous systemsataxiadementiaepilepsyAlzheimer'scerebral palsystrokemotor neuron diseaseParkinson's diseasespinal injuryavulsion injury and peripheral neuropathiescardiovascular diseasediseases affecting the immune systemcancerCrohn's diseaseAIDSHIVlupusceliac diseasediabetesGrave's diseaseGuillain-Barré syndromeAddison's diseaseHashimoto's diseasemyasthenia gravisnarcolepsypernicious anaemiarheumatoid arthritispsoriasisulcerative colitisimmunodeficiency and inflammatory diseasesinherited diseasesgenetic disordershemophiliacystic fibrosis and Huntingdon'ssingle gene disordersbone and blood diseases and reproductive system disorders; pharmacy advice; provision of information relating to medicalsurgical and veterinary matters online from a computer database or over the Internet; exclude services in the field of inhalation technology
Publicações
Histórico de despachos e eventos da marca no USPTO.
63 publicações encontradas
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
22/01/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
21/01/2025
E815
TEAS SECTION 8 & 15 RECEIVED
29/08/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
22/08/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
19/06/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
19/06/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/04/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/04/2018
PUBO
PUBLISHED FOR OPPOSITION
03/04/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/03/2018
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
26/02/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/02/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
13/02/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/02/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
12/02/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/02/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/11/2017
GNRT
NON-FINAL ACTION E-MAILED
27/11/2017
CNRT
NON-FINAL ACTION WRITTEN
27/11/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/11/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
02/11/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
31/10/2017
GNSL
LETTER OF SUSPENSION E-MAILED
31/10/2017
CNSL
SUSPENSION LETTER WRITTEN
31/10/2017
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
31/10/2017
OTHE
CASE RETURNED TO EXAMINATION
31/10/2017
IUCN
NOTICE OF ALLOWANCE CANCELLED
31/10/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/05/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/03/2017
PUBO
PUBLISHED FOR OPPOSITION
14/03/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/02/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/02/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/01/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
31/01/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
31/01/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
31/01/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
31/01/2017
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
15/08/2016
GPRA
PRIORITY ACTION E-MAILED
15/08/2016
CPRA
PRIORITY ACTION WRITTEN
15/08/2016
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
20/07/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/07/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/07/2016
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
14/07/2016
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
20/01/2016
GNSL
LETTER OF SUSPENSION E-MAILED
20/01/2016
CNSL
SUSPENSION LETTER WRITTEN
20/01/2016
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
29/12/2015
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
25/06/2015
GNSL
LETTER OF SUSPENSION E-MAILED
25/06/2015
CNSL
SUSPENSION LETTER WRITTEN
25/06/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/06/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/06/2015
ALIE
ASSIGNED TO LIE
01/06/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
26/05/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
26/11/2014
GNRT
NON-FINAL ACTION E-MAILED
26/11/2014
CNRT
NON-FINAL ACTION WRITTEN
26/11/2014
DOCK
ASSIGNED TO EXAMINER
25/11/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/08/2014
NWAP
NEW APPLICATION ENTERED
15/08/2014
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SOCTEC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.